Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
We need your mantras for a new project! Share with us.
Top Breast Cancer Research at ASCO 2025
moderators
Posts: 10,100
Top Breast Cancer Research at ASCO 2025
Dr. Eleonora Teplinsky explains DESTINY-Breast09, ASCENT-04, and SERENA-6.
Jun 2, 2025
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research.
Listen to the episode to hear Dr. Teplinsky discuss:
- The SERENA-6 trial, which found that if metastatic hormone receptor-positive, HER2-negative breast cancer develops ESR1 mutations during the first hormonal therapy treatment, switching to camizestrant from an aromatase inhibitor before the cancer grows improves outcomes.
- Results from the DESTINY-Breast09 trial showing that the combination of Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Perjeta (chemical name: pertuzumab) is a better first treatment for metastatic HER2-positive breast cancer than the current standard of THP chemo.
- The ASCENT-04/KEYNOTE-D19 trial, which found that people with metastatic PD-L1-positive, triple-negative breast cancer fared better with the combo of Trodelvy (chemical name: sacituzumab govitecan-hziy) and Keytruda (chemical name: pembrolizumab) as a first treatment compared to people who received chemotherapy and Keytruda.
Tagged:
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your profile.